Kana Shiraishi

Kana Shiraishi

Auto-generated profile, based on publicly available information

Kana Shiraishi

Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2021 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
KSKana Shiraishi
Kana Shiraishi
Shinya FurukawaShinya Furukawa
Shinya Furukawa
SYSen Yagi
Sen Yagi
KMKenichirou Mori
Kenichirou Mori
TNTomoyuki Ninomiya
Tomoyuki Ninomiya
YHYoichi Hiasa
Yoichi Hiasa

11 October 2020 in International Journal of Colorectal Disease
Verified
Journal Article
Closed access
PDF file
KSKana Shiraishi
Kana Shiraishi
Shinya FurukawaShinya Furukawa
Shinya Furukawa
SYSen Yagi
Sen Yagi
MHMasakazu Hanayama
Masakazu Hanayama
KMKenichirou Mori
Kenichirou Mori
YHYoichi Hiasa
Yoichi Hiasa

12 September 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
KSKana Shiraishi
Kana Shiraishi
OYOsamu Yoshida
Osamu Yoshida
YIYusuke Imai
Yusuke Imai
SASheikh Mohammad Fazle Akbar
Sheikh Mohammad Fazle Akbar
TSTakahiro Sanada
Takahiro Sanada
YHYoichi Hiasa
Yoichi Hiasa
Hepatitis B vaccine induces the production of antibodies against hepatitis B surface antigen (anti-HBs) and prevents hepatitis B virus (HBV) infection. However, 5–10% of individuals cannot develop anti-HBs even after multiple vaccinations (HB vaccine non-responders). We developed an intranasal vaccine containing both HBs antigen (HBsAg) and HB core antigen (HBcAg) and mixed it with a viscosity enhancer, carboxyl vinyl polymer (CVP-NASVAC). Here, we investigated the prophylactic capacity of CVP-NASVAC in HB vaccine non-responders. Thirty-four HB vaccine non-responders were administered three doses of intranasal CVP-NASVAC. The prophylactic capacity of CVP-NASVAC was assessed by evaluating the induction of anti-HBs and anti-HBc (IgA and IgG) production, HBV-neutralization activity of sera, and induction of HBs- and HBc-specific cytotoxic T lymphocytes (CTLs). After CVP-NASVAC administration, anti-HBs and anti-HBc production were induced in 31/34 and 27/34 patients, respectively. IgA anti-HBs and anti-HBc titers significantly increased after CVP-NASVAC vaccination. HBV-neutralizing activity in vitro was confirmed in the sera of 26/29 CVP-NASVAC-administered participants. HBs- and HBc-specific CTL counts substantially increased after the CVP-NASVAC administration. Mild adverse events were observed in 9/34 participants; no serious adverse events were reported. Thus, CVP-NASVAC could be a beneficial vaccine for HB vaccine non-responders.

30 April 2023 in Annals of Coloproctology
Verified
Journal Article
Open access
PDF file
SYSen Yagi
Sen Yagi
Shinya FurukawaShinya Furukawa
Shinya Furukawa
KSKana Shiraishi
Kana Shiraishi
TMTeruki Miyake
Teruki Miyake
KTKazuhiro Tange
Kazuhiro Tange
YHYoichi Hiasa
Yoichi Hiasa
Purpose: The albumin to globulin ratio (AGR) is a recognized chronic inflammation marker. No evidence regarding the relationship between AGR level and ulcerative colitis (UC) exists. The aim of this study was to evaluate the association between AGR and clinical outcomes among Japanese subjects with UC.Methods: The study subjects consisted of 273 Japanese individuals with UC. AGR was divided into 4 categories (low, moderate, high, and very high). The definition of complete mucosal healing (MH) was based on the Mayo endoscopic subscore of 0. Clinical remission (CR) was defined as no rectal bleeding and no abnormally high stool frequency (<3 times per day).Results: The percentage of MH was 26.4%. High AGR and very high AGR were significantly positively correlated with CR (adjusted odds ratio [OR], 5.85; 95% confidence interval [CI], 2.52–14.18 and adjusted OR, 4.97; 95% CI, 2.14–12.04) and complete MH (adjusted OR, 4.03; 95% CI, 1.56–11.51 and adjusted OR, 5.22; 95% CI, 1.97–14.89), respectively after adjustment for confounding factors (P for trend=0.001). Only in the low C-reactive protein (CRP) group (≤0.1 mg/dL), very high AGR was significantly positively correlated with complete MH but not CR (adjusted OR, 4.38; 95% CI, 1.06–21.77; P for trend=0.017). In the high CRP group, no correlation between AGR and complete MH was found.Conclusion: Among Japanese patients with UC, AGR may be independently positively correlated with complete MH. In particular, among UC patients with low CRP, AGR might be a useful complementary marker for complete MH.

22 August 2024 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
SKShogo Kitahata
Shogo Kitahata
Shinya FurukawaShinya Furukawa
Shinya Furukawa
TMTeruki Miyake
Teruki Miyake
OYOsamu Yoshida
Osamu Yoshida
KSKana Shiraishi
Kana Shiraishi
YHYoichi Hiasa
Yoichi Hiasa